Precision BioSciences Inc
NASDAQ:DTIL

Watchlist Manager
Precision BioSciences Inc Logo
Precision BioSciences Inc
NASDAQ:DTIL
Watchlist
Price: 6.86 USD -5.25% Market Closed
Market Cap: 52.6m USD
Have any thoughts about
Precision BioSciences Inc?
Write Note

Precision BioSciences Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Precision BioSciences Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Precision BioSciences Inc
NASDAQ:DTIL
Cash from Operating Activities
-$48.2m
CAGR 3-Years
-326%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Precision BioSciences Inc
Glance View

Market Cap
51.3m USD
Industry
Biotechnology

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 198 full-time employees. The company went IPO on 2019-03-28. The company is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The firm's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

DTIL Intrinsic Value
12.31 USD
Undervaluation 44%
Intrinsic Value
Price

See Also

What is Precision BioSciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-48.2m USD

Based on the financial report for Sep 30, 2024, Precision BioSciences Inc's Cash from Operating Activities amounts to -48.2m USD.

What is Precision BioSciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
5%

Over the last year, the Cash from Operating Activities growth was 51%. The average annual Cash from Operating Activities growth rates for Precision BioSciences Inc have been -326% over the past three years , 5% over the past five years .

Back to Top